Immunomodulatory activity of resveratrol: discrepant in vitro and in vivo immunological effects.

trans-Resveratrol is a dietary polyphenolic compound present in grapes, which has been shown to exhibit strong anti-inflammatory, antioxidant, and chemopreventive activities. In this study we have compared the in vitro and in vivo effects of resveratrol on the development of various cell-mediated immune responses, including mitogen/antigen-induced T cell proliferation, induction of cytotoxic T lymphocytes (CTLs), interleukin-2 (IL-2) induced lymphokine activated killer cells, and cytokine production. We found significant suppression (>90%) of the mitogen/antigen-induced T cell proliferation and development of allo-antigen specific CTLs in vitro with resveratrol at a concentration of 25 microM. Intragastric administration of resveratrol (2 mg daily) to mice for 4 weeks showed no effect on age-related gain in body weight, peripheral blood cell counts (WBC, RBC, or platelets), or the cellularity of bone marrow or spleen. The CD4(+) and CD8(+) T cells in spleen or colony-forming units-total in the marrow also remained unaffected by treatment with resveratrol. Spleen cells, which were stimulated in vitro after being removed from mice which had been administered resveratrol for 2 or 4 weeks, showed no significant change in IL-2 or concanavalin A induced proliferation of T cells or production of IL-2 induced lymphokine activated killer cells. Further, the production of in interferon-gamma and IL-12 was not affected by administration of resveratrol, but production of tumor necrosis factor-alpha was reduced. Even when conducted entirely in vivo, treatment with resveratrol was found to only marginally reduce allo-antigen induced T cell proliferation and the generation of CTLs in the draining lymph nodes. Thus, even though resveratrol strongly inhibits T cell proliferation and production of cytolytic cells in vitro, oral administration of resveratrol for 4 weeks does not induce hematologic or hematopoietic toxicity, and only marginally reduces the T cell-mediated immune responses.

[1]  L. Bavaresco,et al.  Antiplatelet activity of cis-resveratrol. , 1996, Drugs under experimental and clinical research.

[2]  M. De la Fuente,et al.  Anti‐oxidants as modulators of immune function , 2000, Immunology and cell biology.

[3]  S. Gautam,et al.  Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging , 2000, Bone Marrow Transplantation.

[4]  A. Shah,et al.  Synergy between ethanol and grape polyphenols, quercetin, and resveratrol, in the inhibition of the inducible nitric oxide synthase pathway. , 2000, Biochemical pharmacology.

[5]  L. Frémont,et al.  Interaction of transresveratrol with plasma lipoproteins. , 1998, Biochemical pharmacology.

[6]  E. Diamandis,et al.  Absorption of trans-resveratrol in rats. , 2001, Methods in enzymology.

[7]  G. Ravagnan,et al.  Effects of resveratrol on human immune cell function. , 2001, Life sciences.

[8]  J. Pezzuto,et al.  Human, Rat, and Mouse Metabolism of Resveratrol , 2002, Pharmaceutical Research.

[9]  T. Hsieh,et al.  Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. , 1999, Experimental cell research.

[10]  D. Goldberg,et al.  Beyond alcohol: beverage consumption and cardiovascular mortality. , 1995, Clinica chimica acta; international journal of clinical chemistry.

[11]  G. Serrero,et al.  Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells , 1999, Journal of cellular physiology.

[12]  L. Frémont,et al.  Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. , 1997, Biochemical pharmacology.

[13]  Norman R. Farnsworth,et al.  Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes , 1997, Science.

[14]  A. Miller,et al.  Diet and cancer. A review. , 1990, Acta oncologica.

[15]  S. Kuo,et al.  Dietary flavonoid and cancer prevention: evidence and potential mechanism. , 1997, Critical reviews in oncogenesis.

[16]  J. Marier,et al.  Metabolism and Disposition of Resveratrol in Rats: Extent of Absorption, Glucuronidation, and Enterohepatic Recirculation Evidenced by a Linked-Rat Model , 2002, Journal of Pharmacology and Experimental Therapeutics.

[17]  A. Contestabile,et al.  Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats , 2000, Neuroscience Letters.

[18]  Kimura Yoshiyuki,et al.  Effects of stilbenes on arachidonate metabolism in leukocytes. , 1985 .

[19]  R. S. Lee,et al.  Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. , 2000, Cardiovascular research.

[20]  Y. Surh,et al.  Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. , 1999, Mutation research.

[21]  P. Langcake,et al.  The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury , 1976 .

[22]  J. Carretero,et al.  Inhibition of cancer growth by resveratrol is related to its low bioavailability. , 2002, Free radical biology & medicine.

[23]  A. Waterhouse,et al.  Inhibition of human LDL oxidation by resveratrol , 1993, The Lancet.

[24]  E. Diamandis,et al.  The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. , 1995, Clinica chimica acta; international journal of clinical chemistry.

[25]  J. J. Moreno Resveratrol modulates arachidonic acid release, prostaglandin synthesis, and 3T6 fibroblast growth. , 2000, The Journal of pharmacology and experimental therapeutics.

[26]  S. Renaud,et al.  Wine, alcohol, platelets, and the French paradox for coronary heart disease , 1992, The Lancet.

[27]  N. Seiler,et al.  Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. , 2000, Cancer letters.

[28]  W. Willett,et al.  Diet and health: what should we eat? , 1994, Science.

[29]  G A Colditz,et al.  Dietary fat intake and the risk of coronary heart disease in women. , 1997, The New England journal of medicine.

[30]  M. Vinardell,et al.  Nutrient Interactions and Toxicity Research Communication The Daily Oral Administration of High Doses of trans-Resveratrol to Rats for 28 Days Is Not Harmful , 2002 .

[31]  P. Schnohr,et al.  Mortality associated with moderate intakes of wine, beer, or spirits , 1995, BMJ.

[32]  M. Fontecave,et al.  Resveratrol, a remarkable inhibitor of ribonucleotide reductase , 1998, FEBS letters.

[33]  N. Seiler,et al.  Resveratrol Inhibits Intestinal Tumorigenesis and Modulates Host-Defense-Related Gene Expression in an Animal Model of Human Familial Adenomatous Polyposis , 2001, Nutrition and cancer.

[34]  C. Cerletti,et al.  Effect of trans‐resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function , 1998, British journal of pharmacology.

[35]  L. Wattenberg Inhibition of carcinogenesis by minor dietary constituents. , 1992, Cancer research.

[36]  L. Racioppi,et al.  Resveratrol arrests the cell division cycle at S/G2 phase transition. , 1998, Biochemical and biophysical research communications.

[37]  Xiaohua Gao,et al.  Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. , 2001, Biochemical pharmacology.

[38]  J. Constant Alcohol, ischemic heart disease, and the french paradox , 1997, Clinical cardiology.

[39]  G. Block,et al.  Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. , 1992, Nutrition and cancer.

[40]  R. Snapka,et al.  DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. , 1998, Journal of natural products.

[41]  J. Russo,et al.  Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. , 1998, International journal of oncology.